Valneva SE (VALN) Accounts Payables (2020 - 2026)
Valneva SE (VALN) posted quarterly Accounts Payables of $24.8 million for Q1 2026, down 21.66% year-on-year from $31.7 million in Q1 2025, and down 11.14% on a QoQ basis from $27.9 million in Q4 2025.
Valneva SE (VALN) Accounts Payables (2020 - 2026) Analysis & Trends
Valneva SE (VALN) has reported Accounts Payables for 7 consecutive years, with $24.8 million the latest figure, recorded in Q1 2026.
- Quarterly Accounts Payables fell 21.66% year-over-year to $24.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.8 million (down 21.66% YoY) and the FY2025 annual result came in at $27.9 million, down 30.92% from the prior year.
- Accounts Payables fell to $24.8 million in Q1 2026 per VALN's latest filing, from $27.9 million in the prior quarter.
- Over the last five years, Accounts Payables for VALN reached as high as $107.2 million in Q3 2023 and fell as low as $24.0 million in Q2 2025.
- A 5-year average of $52.1 million and a median of $40.4 million in 2024 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2023 — Accounts Payables advanced 25.7% — and 2024, when it tumbled 54.48%.
- Year by year, Accounts Payables stood at $47.2 million in 2022, then climbed by 6.78% to $50.4 million in 2023, then slipped by 19.82% to $40.4 million in 2024, then sank by 30.92% to $27.9 million in 2025, then declined by 11.14% to $24.8 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $24.8 million, $27.9 million, and $34.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 5.74 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 10.62 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 423.55 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 694,346.76 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 489.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.03 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.52 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 80.54 Mn |
| 10 | Valneva SE | 803.90 Mn | 680.66 Mn | 5.38 Mn | 24.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.81 Mn |
| Dec 31, 2025 | 27.93 Mn |
| Sep 30, 2025 | 34.27 Mn |
| Jun 30, 2025 | 24.03 Mn |
| Mar 31, 2025 | 31.67 Mn |
| Dec 31, 2024 | 40.42 Mn |
| Sep 30, 2024 | 48.81 Mn |
| Jun 30, 2024 | 37.15 Mn |
| Mar 31, 2024 | 38.13 Mn |
| Dec 31, 2023 | 50.41 Mn |
| Sep 30, 2023 | 107.24 Mn |
| Jun 30, 2023 | 78.69 Mn |
| Mar 31, 2023 | 38.14 Mn |
| Dec 31, 2022 | 47.21 Mn |
| Sep 30, 2022 | 85.32 Mn |
| Jun 30, 2022 | 95.25 Mn |
| Mar 31, 2022 | 75.41 Mn |
| Dec 31, 2021 | 77.52 Mn |
| Dec 31, 2020 | 41.21 Mn |